Educational content only. Not legal or regulatory advice.

Interest in peptides has exploded—alongside confusion about labels like “Research Use Only (RUO)”, compounding, and what “approved” actually means. This guide outlines core concepts so readers can interpret claims they see online.

“Research Use Only” (RUO) is not for human use

FDA guidance explains RUO/IUO labels in the context of in vitro diagnostic products: RUO items are for laboratory research and not for clinical use. Selling products intended for human use while labeled RUO can trigger enforcement because the label doesn’t match the real-world intended use. The same principle—intended use governs—carries across product categories. U.S. Food and Drug Administration

Why cGMP and ICH Q7 matter

Manufacturing active pharmaceutical ingredients (APIs)—including peptide APIs for human drugs—must follow current Good Manufacturing Practice (cGMP). The internationally harmonized ICH Q7 guideline lays out quality systems, documentation, impurity control, and validation (e.g., blending, particle size, stability). Compliance helps ensure identity, purity, and consistency—attributes consumers can’t verify on their own. U.S. Food and Drug Administration+2U.S. Food and Drug Administration+2

Recent enforcement around unapproved GLP-1–related products

Regulators have specifically warned online vendors selling unapproved semaglutide, tirzepatide, or retatrutide products—sometimes mislabeled as “for research only” but clearly marketed for human use. FDA warning letters and advisories emphasize that such products are unapproved drugs of unknown quality. News coverage and public letters document actions against multiple vendors. U.S. Food and Drug Administration+2U.S. Food and Drug Administration+2

Compounding isn’t a shortcut to approval

Separate from mass-manufactured drugs, compounding is permitted under specific conditions, but not as a way to make general copies of approved, commercially available products. Recent litigation highlights restrictions on mass compounding of GLP-1 agents absent an FDA-declared shortage, reinforcing that compounded copies aren’t automatically lawful alternatives. Reuters

Reading claims you see online

• Look for approval status. Is there an FDA-approved drug with the same active ingredient and route, or is it investigational? The answer changes what standards apply. U.S. Food and Drug Administration
• RUO ≠ human use. If a site sells “RUO” peptides with dosing instructions or promises of human outcomes, that’s a red flag on intended use. U.S. Food and Drug Administration
• Quality is a process, not a label. Ask whether the API was made under ICH Q7/cGMP and whether there’s documentation of identity, purity, and impurities. U.S. Food and Drug Administration+1

Bottom line

Quality, safety, and legality hinge on intended use and manufacturing standards. RUO products are for the lab; drug-grade peptide APIs require cGMP; and unapproved products marketed for human use draw enforcement attention. For any specific therapeutic question, readers should rely on healthcare professionals and official drug labeling. U.S. Food and Drug Administration+1